1BA Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study

European Journal of Cancer ◽

10.1016/s0959-8049(12)70068-0 ◽

2012 ◽

Vol 48 ◽

pp. S37 ◽

Cited By ~ 3

Author(s):

C. Jackisch ◽

D. Stroyakovskiy ◽

S. Muehlbauer ◽

D. Heinzmann ◽

M.V. Kopp ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Phase Iii ◽

Her2 Positive ◽

Open Label

Download Full-text

Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study

10.1158/1538-7445.sabcs19-pd4-07 ◽

2020 ◽

Author(s):

Antoinette R Tan ◽

Seock-Ah Im ◽

Andre Mattar ◽

Ramon Colomer ◽

Daniil Stroyakovskii ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Primary Analysis ◽

Her2 Positive ◽

Open Label ◽

Dose Combination

Download Full-text

Additional Safety Results of Hannah: A Phase III Randomised, Open-Label, International Study of the Subcutaneous Formulation of Trastuzumab (H) in HER2-Positive Early Breast Cancer Patients

Annals of Oncology ◽

10.1016/s0923-7534(20)32833-7 ◽

2012 ◽

Vol 23 ◽

pp. ix102-ix103

Author(s):

C. Jackisch ◽

M. Dank ◽

G. Frasci ◽

K.H. Park ◽

R.I. Lopez ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Breast Cancer ◽

International Study ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Additional Safety

Download Full-text

Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study

The Breast ◽

10.1016/s0960-9776(17)30116-9 ◽

2017 ◽

Vol 32 ◽

pp. S27

Author(s):

S. Talayeva ◽

D. Kaidarova ◽

E. Zhavrid ◽

A. Prokharau ◽

N. Antonenkova ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

Phase Iiib

Download Full-text

46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study

Annals of Oncology ◽

10.1016/j.annonc.2021.03.060 ◽

2021 ◽

Vol 32 ◽

pp. S40-S41

Author(s):

S-A. Im ◽

A.R. Tan ◽

A. Mattar ◽

R. Colomer ◽

D. Stroyakovskii ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Injection ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Dose Combination

Download Full-text

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

European Journal of Breast Health ◽

10.4274/ejbh.galenos.2021.2021-9-9 ◽

2022 ◽

Vol 18 (1) ◽

pp. 63-73

Author(s):

İrfan Cicin ◽

Mohammed Oukkal ◽

Hassen Mahfouf ◽

Amel Mezlini ◽

Blaha Larbaoui ◽

...

Keyword(s):

Breast Cancer ◽

Patient Satisfaction ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

Phase Iiib

Download Full-text

An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

European Journal of Cancer ◽

10.1016/s0959-8049(18)30535-5 ◽

2018 ◽

Vol 92 ◽

pp. S102-S103 ◽

Cited By ~ 1

Author(s):

I. Ciçin ◽

M. Oukkal ◽

H. Mahfouf ◽

A. Mezlini ◽

B. Larbaoui ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Adjuvant Setting ◽

Her2 Positive ◽

Open Label ◽

Safety And Efficacy ◽

Phase Iiib

Download Full-text

Abstract PD3-11: Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study

10.1158/1538-7445.sabcs17-pd3-11 ◽

2018 ◽

Author(s):

C Jackisch ◽

D Stroyakovskiy ◽

X Pivot ◽

J-S Ahn ◽

B Melichar ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Final Analysis ◽

Phase Iii ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label

Download Full-text

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04024462 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Efficacy And Safety ◽

Her2 Positive ◽

Dose Combination

Download Full-text

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00122-4 ◽

2021 ◽

Author(s):

José Manuel Pérez-García ◽

Geraldine Gebhart ◽

Manuel Ruiz Borrego ◽

Agostina Stradella ◽

Begoña Bermejo ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Fdg Pet ◽

Pathological Response ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

18F Fdg

Download Full-text

Abstract OT-01-02: Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2- early breast cancer

10.1158/1538-7445.sabcs20-ot-01-02 ◽

2021 ◽

Author(s):

Oleg Gluz ◽

Tom Degenhardt ◽

Norbert Marschner ◽

Matthias Christgen ◽

Hans Heinrich Kreipe ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Adjuvant Endocrine Therapy ◽

Phase Iii ◽

Open Label ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Open Label Phase

Download Full-text